Merck & Co. and Isomorphic Labs will combine artificial-intelligence drug design with Merck’s pharmaceutical development infrastructure to pursue small-molecule drug candidates for an undisclosed oncology target.
The companies announced the strategic research collaboration Nov. 19, 2026. They described the target as strategically important but did not identify it, disclose the number of candidates or provide a development timetable.
Using its IsoDDE drug-design engine and selected proprietary data sets from Merck, Isomorphic will produce computational predictions and proposed molecular structures. Merck will take responsibility for preclinical and clinical development, manufacturing and commercialization of any products that emerge from the program.
The companies did not disclose the upfront payment or potential milestone amounts. Isomorphic will be eligible for research, development, regulatory and commercial milestones, as well as tiered royalties on net sales. It can also choose to co-fund development activities in exchange for elevated royalties.
“The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” George Addona, senior vice president and head of discovery, preclinical development and translational medicine at Merck Research Laboratories, said in the announcement.
Sarah Skerratt, Isomorphic’s chief research officer, said the company would apply IsoDDE through its collaboration with MSD, Merck’s name outside the United States and Canada, to advance drug discovery.
The arrangement gives Isomorphic responsibility for computational discovery while Merck supplies selected data and manages later-stage execution. Isomorphic describes IsoDDE as a modality-agnostic engine built from foundational AI models.
Isomorphic Labs was founded in 2021. The London-based company is led by CEO Sir Demis Hassabis and President Max Jaderberg, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.



